P53 Her2/neu as prognostic factors in advanced non-small cell lung cancer (NSCLC) treated with paclitaxel

被引：0
|
作者：
Yumuk, R
Turhal, N
Ahiskali, R
Gumus, M
Hatabay, N
Turken, O
Ozkan, A
Salepci, T
Aliustaoglu, M
机构：
[1] Marmara Univ Hosp, Div Med Oncol, Istanbul, Turkey
[2] Marmara Univ Hosp, Dept Pathol, Istanbul, Turkey
[3] Dr Lutfi Kirdar Res & Training Hosp, Oncol Unit, Istanbul, Turkey
[4] SSK Sureyyapasa Chest & Cardiovasc Dis Hosp, Oncol Unit, Istanbul, Turkey
[5] Gulhane Mil Med Acad, Div Med Oncol, Istanbul, Turkey
[6] Haydarpasa Numune Res & Training Hosp, Oncol Unit, Istanbul, Turkey
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S152 / S152
页数：1
相关论文
共 50 条
  • [41] P53 codon 72 polymorphism increases the risk of somatic P53 gene mutations in non-small cell lung cancer (NSCLC)
    Szymanowska, A
    Jassem, E
    Dziadziuszko, R
    Borg, A
    Limon, J
    Kobierska-Gulida, G
    Skokowski, J
    Jassem, J
    LUNG CANCER, 2005, 49 : S75 - S75
  • [42] Atelectasis as a good prognostic factor for advanced non-small cell lung cancer (NSCLC)
    Dediu, Mircea
    Anghel, Rodica
    Median, Dragos
    Alexandru, Aurelia
    Nutu, Dumitru
    Tarlea, Alin
    Silaghi, Anca
    Vremes, Georgeta
    Gal, Cristian
    Nedelus, Loredana
    ANNALS OF ONCOLOGY, 2006, 17 : 231 - 232
  • [43] Correlation of p53 genotype and response to induction chemotherapy in advanced non small cell lung cancer (NSCLC).
    Kandioler, D
    Kappel, S
    Eberhardt, W
    Stamatis, G
    Mittelböck, M
    Bachleitner-Hoffmann, T
    Zöchbauer-Müller, S
    Aigner, C
    Klepetko, W
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 631S - 631S
  • [44] Relation between P53 codon 72 polymorphism and somatic P53 gene mutation in non-small cell lung cancer (NSCLC)
    Jassem, J.
    Szymanowska, A.
    Jassem, E.
    Dziadziuszko, R.
    Borg, A.
    Limon, J.
    Kobierska-Gulida, G.
    Skokowski, J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 336 - 336
  • [45] Prognostic relevance of p53, Bcl-2, and Bax expression in non-small-cell lung cancer (NSCLC)
    Dworakowska, D
    Faran, G
    Kobierska-Gulida, G
    Sygut, J
    Kopczynski, J
    Bosse, A
    Dorn, K
    Skokowski, J
    Jassem, J
    Jassem, E
    LUNG CANCER, 2004, 45 : S30 - S31
  • [46] Tolerability and activity of weekly paclitaxel and carboplatin in advanced non-small cell lung cancer (NSCLC)
    Fabi, A
    De Marco, S
    Barduagni, M
    Gamucci, T
    Cortesi, E
    De Marinis, F
    Ferraresi, V
    Saltarelli, R
    Gabriele, A
    Accettura, C
    Cognetti, F
    ANNALS OF ONCOLOGY, 2000, 11 : 4 - 4
  • [47] Phase II study of oxaliplatin and paclitaxel in advanced non-small cell lung cancer (NSCLC).
    Mauer, AM
    Otterson, G
    Rudin, CM
    Villalona, M
    Ansari, RH
    Szeto, L
    Vokes, EE
    CLINICAL CANCER RESEARCH, 2000, 6 : 4576S - 4576S
  • [48] Concurrent chemoradiotherapy with paclitaxel and carboplatin for locoregionally advanced non-small cell lung cancer (NSCLC)
    Kaplanova, J.
    Tomiskova, M.
    Babickova, L.
    Kadlec, B.
    Slampa, P.
    Skrickova, J.
    LUNG CANCER, 2006, 52 : S34 - S34
  • [49] Phase II study of paclitaxel and gemcitabine in advanced non-small cell lung cancer (NSCLC).
    Lazaro, M
    Jorge, M
    Castellanos, J
    ANNALS OF ONCOLOGY, 2000, 11 : 109 - 109
  • [50] Real-World Characteristics and Outcomes Among Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) and HER2 Mutations
    Bath, Christina
    Le, Xiuning
    Lovly, Christine M.
    Patil, Tejas
    Maruti, Sonia S.
    Stanhope, Stephen A.
    Herbert, Stephan
    Nagasaka, Misako
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E49 - E50
12345